Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  

| More

Top brokerage houses have given 'subscribe' rating for Windlas Biotech Ltd IPO

Posted On: 2021-08-03 17:29:55 (Time Zone: UTC)

Top brokerage houses have given 'subscribe' rating for the IPO of Windlas Biotech Ltd, a leading Contract Development Manufacturing Organisation (CDMO) with a focus on the chronic therapeutic category.

With more than two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms, WBL provides a comprehensive range of CDMO services including product discovery, product development, licensing and commercial manufacturing of generic products.

"Its innovative portfolio of complex generic products supported by robust R&D capabilities, efficient and quality compliant manufacturing facilities with significant entry barriers, long-term relationships with Indian pharmaceutical companies and a consistent track record of financial performance provide for further growth visibility," said BP Equities in a report.

"On the valuation front, at the upper price band, the issue is aggressively priced at 64.4x P/E considering the diluted equity shares and FY21 annualized earnings. However, considering all the positive factors mentioned above, we give a "SUBSCRIBE" rating on this issue for the long term," it further said.

In FY2020, Windlas provided CDMO services to 7 of the top 10 Indian formulations pharmaceutical companies. The domestic formulations CDMO is projected to grow at a CAGR of approximately 14%. Further, the Government of India has approved the Production Linked Incentive ("PLI") scheme for pharmaceuticals for FY2021 to FY2029, which is expected to promote innovation for development of complex and high-tech products.

"With its superior product mix, established brand name, strong Relationships with Leading Pharma Companies, and adding capacities, we believe the company is well placed to capitalize on domestic opportunities. At the upper price band of Rs.460/-, stock is valued at 26.8x of FY21 Earnings of Rs.17.1(based on fully diluted post issue equity and adjustment of exceptional item of 22Cr)," said Asit C Mehta Securities.

"We recommend to subscribe the issue from a long-term prospective," it further said.

With increasing globalization and focus of large pharmaceutical players on cutting costs and optimizing operations, CDMOs have seen significant acceptance in the pharmaceutical industry internationally over the last few years.

Windlas has developed relationships with leading Indian pharmaceutical companies. Their operational track record in successful delivery of products, responsiveness, dosage innovation, complex generic product development, quality and technical standards, turnaround times, and productivity has facilitated the strengthening of their customer base and helped them in expanding their product and service offerings as well as geographic reach.

In FY2020, they provided CDMO services to 7 of the top 10 Indian formulations pharmaceutical companies.

The company is also entering into injectables CDMO industry.

The domestic injectables CDMO industry is expected to reach Rs.49 billion to Rs.53 billion by FY2025. Moreover, the injectables segment is expected to account for 12% to 13% of all the dosage forms in the domestic formulations market and 13.2% to 14.2% of the domestic formulations CDMO market in FY2025. Further, the margins for contract manufacturers in the injectables segment are more robust as there are fixed contracts for the development and manufacturing of the drugs and there are no selling and general costs for the contract manufacturers. Accordingly, Windlas proposes to utilize Rs.50 crore of their Net Proceeds towards capital expenditure for capacity expansion. Further, the business to business model also allows opportunity for scaling up operations as the players can specialize in particular molecule and have supply contracts with multiple injectables marketing players.

It has consistent track record of financial performance. In the last three years (FY19-21), the company's revenue and operating profit has grown at a CAGR of 18% and 19% respectively. They have received ICRA A (Stable) and ICRA A1 rating from ICRA. As of March 31, 2021, the Total Debt/ Equity ratio was 0.16, and ROCE was 20.23%. They have consistently experienced an improvement in their PAT margin from 4.65% in Fiscal 2019 to 8.70% in Fiscal 2021, on account of cost rationalization strategies, increased focus on complex generic products in the chronic therapeutic category.

According to GEPL Capital, WBL has strong R&D and manufacturing capabilities with long term client relationships with marquee pharma companies and it has recommend a subscribe rating to the issue.

"WBL has reported a steady increase in business with improving profitability. On the back of increased sales from the existing customers, addition of new CDMO products & customers and improved business from the domestic trade generics & OTC brands, the company has reported a 6.7% CAGR rise in consolidated business over FY18-21 to Rs. 427.6cr in FY21," Choice Broking said.

Shares of 20 Microns Limited was last trading in BSE at Rs. 68.1 as compared to the previous close of Rs. 66.55. The total number of shares traded during the day was 25111 in over 525 trades.

The stock hit an intraday high of Rs. 70.05 and intraday low of 65.75. The net turnover during the day was Rs. 1720672.

Source: Equity Bulls

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

Automobile Sector - Monthly Quick View - Aug'21 - Mixed Performance across Segments - Reliance Securities

Axis Securities initiating coverage on ICICI Securities

Company Update - Minda Corporation - Q1FY22 - ICICI Direct

Quant Pick - PVR Ltd - ICICI Direct

Quant Pick - ONGC - ICICI Direct

Peak in the headline wholesale inflation is behind us - WPI August 2021 - Acuité Ratings

Sansera Engineering - IPO - Strong Outlook with Steady Cash Flow - Reliance Securities

APL Apollo Tubes - Journey from a semi-commodity player to a branded one - HDFC Securities

Nazara Technologies Ltd - Upbeat in medium-term, Uncertain over Long-term - YES Securities

IPO Review - Sansera Engineering Ltd - ICICI Direct

Overall index is still 0.3% lower than the pre-pandemic levels - IIP July 2021

YES SECURITIES on Monthly General Insurance & Mutual Funds Data

India urban logistics spaces expected to cross 7 million sq. ft by 2022: JLL

Neogen Chemicals - Breaking into the next orbit with a bang - HDFC Securities

Gladiator Stocks - Bharti Airtel Ltd - ICICI Direct

Gladiator Stocks - V-Guard - ICICI Direct

Balkrishna Industries - Industry export growth accelerates - ICICI Securities

HDFC Life Insurance - Exide Life Acquisition - Maintain ADD - YES Securities

Gladiator Stocks - Grindwell Norton - ICICI Direct

Gladiator Stocks - Godrej Properties - ICICI Direct

Monthly Auto Volumes - August 2021 - ICICI Direct

Stock Tales - Easy Trip Planners - ICICI Direct

IPO Review - Vijaya Diagnostic Centre Ltd - ICICI Direct

AU Small Finance Bank - Attrition at top level remains key challenge; business momentum sustained in Jul/Aug'21 - ICICI Securities

Gladiator Stocks - State Bank of India - ICICI Direct

Gladiator Stocks - PNC Infratech - ICICI Direct

Vijaya Diagnostic Centre Ltd - IPO Note - YES Securities

Consumer Durables Sector - Lockdown mars performance yet again - Institutional Research Desk at HDFC Securities

75% of the employees today want to be in office at least once a week as compared to 52% in October 2020: JLL

Gladiator Stocks - Safari Industries - ICICI Direct

Gladiator Stocks - Interglobe Aviation - ICICI Direct

IPO Review - Ami Organics Ltd - ICICI Direct

Q1FY22 GDP - 31st Aug 2021 - Acuité Ratings & Research

Avanti Feeds - Higher input prices hurt margins - ICICI Securities

Company Update - Restructuring - Aarti Industries - ICICI Direct

Q1FY22 Company Update - MM Forgings - ICICI Direct

Company Update - Arvind Fashions - ICICI Direct

Zomato - Can margins and multiples surprise? - ICICI Securities

Ujjivan Small Finance Bank - Top management change and lumpy provisioning concern to weigh on valuation in near term - ICICI Securities

Bharat Dynamics - Guided missile systems to drive orderbook and profit growth - ICICI Securities

Economy - Continued accommodation necessary despite inflationary risks: MPC minutes - ICICI Securities

InterGlobe Aviation - Annual report analysis: Liquidity management remains the mainstay in anticipation of traffic recovery - ICICI Securities

General insurance - Health remains dominant growth driver; Strong all-round performance by Bajaj Allianz - ICICI Securities

Earnings Wrap Q1FY22: Resilient earnings, limited impact of second Covid wave - ICICI Direct

Fine Organic Industries Results Review - In-line performance - HDFC Securities

Power Plus Sector Update - July witnessed strong ~10% generation growth - HDFC Securities

Information Technology Sector Update - 'Hit Refresh' - HDFC Securities

Maintain ADD on JK Cement - Healthy performance - HDFC Securities

Maintain BUY on Star Cement - Margin recovers on pricing gain - HDFC Securities

Maintain BUY on Sadbhav Engineering - Long road to recovery - HDFC Securities

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020